Sentences with phrase «in cystic fibrosis patients»

The typical dosage of NAC given as an oral supplement in clinical trials is 600 mg b.i.d., although 200 mg t.i.d. has been shown to provide benefit in just 8 weeks.27 On the other hand, doses as high as 1 gram t.i.d. have been used in cystic fibrosis patients for 4 - 12 weeks with no adverse effects, and in AIDs patients, oral NAC doses up to 8 grams / day did not cause clinically significant adverse reactions.42 43 44 45 46 47

«As a result of studying these proteins, we discovered novel structures that turn out to work very well against bacterial infections, including the complicated bacterial populations in lung infections in cystic fibrosis patients.»

Dental plaque may be the best - known example of a biofilm, but these slimy aggregates of bacteria also play major roles in such chronic infections as those in the urinary tract or in the lungs in cystic fibrosis patients.

Once limited to burn wounds, P. aeruginosa now causes severe hospital - acquired infections and persistent lung infections in cystic fibrosis patients.

The findings help explain why lung infections in cystic fibrosis patients are so hard to treat.

The finding supports the notion of adding a base (a substance with higher pH) to certain inhaled treatments that can be given along with antibiotics, for example in cystic fibrosis patients.

Not exact matches

After being a nurse in the PICU, I thought about all of the genetic disorders my patients had encountered, (i.e. various cancers, cystic fibrosis, muscular dystrophy) and I wondered if there were anyway stem cells could have cured or at least improved their conditions.

In addition, clinicians have long known that cystic fibrosis patients with stable lung function who do not lose weight are more likely to live longer.

The scientists performed the tests in a laboratory setting using 100 different bacterial strains isolated from the lungs of pediatric cystic fibrosis patients of Seattle Children's Hospital and 42 bacterial strains isolated from hospitalized adult patients at UPMC.

In lab experiments using tissue samples cultured from cystic fibrosis patients, scientists at the UNC School of Medicine and the UNC Marsico Lung Institute have shown that a new CF drug counteracts the intended beneficial molecular effect of another CF drug.

«The trial is important for gene research and may be a proof of principle that targeting the most common mutation in cystic fibrosis is an effective approach for treatment of most patients,» Gentzsch said.

We hope this leads to the ability to design, study and test new therapies for every patient on their own cells in the lab, leading to new treatments and breakthroughs in personalized medicine for individuals with a variety of lung diseases, including cystic fibrosis,» explained lead author Katherine McCauley, a PhD student at BUSM.

In the Netherlands, based on research reported in 2016 in Science Translational Medicine, Clevers and colleagues are already using personalized gut organoids, derived from rectal biopsies, to test whether cystic fibrosis patients will benefit from available drugIn the Netherlands, based on research reported in 2016 in Science Translational Medicine, Clevers and colleagues are already using personalized gut organoids, derived from rectal biopsies, to test whether cystic fibrosis patients will benefit from available drugin 2016 in Science Translational Medicine, Clevers and colleagues are already using personalized gut organoids, derived from rectal biopsies, to test whether cystic fibrosis patients will benefit from available drugin Science Translational Medicine, Clevers and colleagues are already using personalized gut organoids, derived from rectal biopsies, to test whether cystic fibrosis patients will benefit from available drugs.

«Because airway spheres from a patient with cystic fibrosis do not swell in our assay but airway spheres from a healthy person do, we can see whether adding a certain drug or combination of drugs causes them to swell more.

In cystic fibrosis, a serious genetic disease that causes recurring lung infections, bacteria colonize a patient's lungs, usually beginning in childhood, leading to difficulty breathinIn cystic fibrosis, a serious genetic disease that causes recurring lung infections, bacteria colonize a patient's lungs, usually beginning in childhood, leading to difficulty breathinin childhood, leading to difficulty breathing.

A multi-drug resistant infection that can cause life - threatening illness in people with cystic fibrosis (CF) and can spread from patient to patient has spread globally and is becoming increasingly virulent, according to new research published today in the journal Science.

Although scientists first mapped the genetic structure of P. aeruginosa 15 years ago, efforts to pinpoint how it behaves during an infection and which genes would need to be turned off to stop its spread have been hampered in part by the difficulty of mimicking the unique conditions of a cystic fibrosis patient's lungs.

A therapy that replaces the faulty gene responsible for cystic fibrosis in patients» lungs has produced encouraging results in a major UK trial.

Substances produced by a harmful bacterium in the lungs of cystic fibrosis patients may enhance the growth of other bacteria that, in turn, inhibit the harmful bacterium's biofilm, according to new research published in PLOS Pathogens.

Substances produced by a harmful bacterium in the lungs of cystic fibrosis patients may enhance the growth of other bacteria that, in turn, inhibit the harmful bacterium's biofilm, according to new research.

«In some patients with cystic fibrosis, this approach has reversed a disease once thought unstoppable.

Steve: You — in the cystic fibrosis section of the book — you profile a doctor who is explaining to one of his patients that the difference between feeling good 99.5 and 99.95 percent of the time on any given day, works out to completely different outcomes over the course of a year.

Patients with Parkinson's disease, cardiovascular disease, and cystic fibrosis may have something in common: cells in their disease - affected tissues may produce misfolded proteins that are incapable of functioning normally.

The first of many probable applications will likely be the chronic bacterial infections in the lungs of cystic fibrosis patients «that frequently develop resistance to all standard antibiotics, and are the leading cause of death in these patients,» says senior author Ronald Montelaro.

How do microbes duke it out in the lungs of cystic fibrosis patients?

Patients undergoing gene therapy for cystic fibrosis at the Royal Brompton Hospital in London, for example, have not been confined to the laboratory.

If effective in humans, the vaccine could help control a dangerous form of pneumonia that mainly afflicts hospitalized patients and individuals with cystic fibrosis.

Experts agree the treatment is transformative for patients with the Cheevers» form of CF. «We have just started using it in practice,» says Henry Dorkin, a pediatric pulmonary specialist and director of the Cystic Fibrosis Center at Children's Hospital in Boston.

Ten Years of Improvement Innovation in Cystic Fibrosis Care includes reports on a range of improvement initiatives, ranging from the impact of patient education on improving adherence to critical daily treatments, and strategies for boosting nutritional status.

New research comparing cystic fibrosis patients in the United States and Canada showed that, although the patients» nutritional status and lung function improved in both countries over the period from 1990 to 2013, the rate of improvement was faster in the United States.

And the technique will benefit not just cancer research but research into every disease driven by gene mutations, from cystic fibrosis to Alzheimer's disease — ultimately enabling customized treatments for patients in a way never before possible.

Ivacaftor is the first drug to treat the underlying causes of cystic fibrosis rather than just its symptoms and is currently approved for patients with the «celtic gene» mutation carried by about four per cent of all patients and 10 - 15 per cent of patients in Ireland.

In patients with cystic fibrosis, the mutations to CFTR render it unable to carry out its normal tasks.

The study was funded by the U.S. Cystic Fibrosis Foundation using data from 45,456 patients in the U.S. Cystic Fibrosis Foundation Registry and 5,941 patients in the Canadian Cystic Fibrosis Registry from 1990 to 2013.

VANCOUVER, CANADA — There's a war going on in the lungs of patients with cystic fibrosis.

Together, these communication and defense capabilities allow P. aeruginosa to form tightly packed layers called biofilms, which can cause respiratory tract infections in humans and are particularly dangerous to cystic fibrosis patients.

Twelve patients from the Northern Ireland Adult and Paediatric Cystic Fibrosis Centres participated in the study.

The study, funded by the U.S. Cystic Fibrosis Foundation, used data from 37,772 patients in the U.S. Cystic Fibrosis Foundation Registry and 5,149 patients in the Canadian Cystic Fibrosis Registry.

Dr. Stephenson's paper is based on data of about 5,000 patients in the Canadian Cystic Fibrosis Registry, of which she is the director.

Infections with these organisms in patients with chronic lung diseases like cystic fibrosis represent an enormous challenge in medical therapy.

Although advances in the understanding and treatment of cystic fibrosis have allowed many people with the condition to live into their early 40s, many patients with cystic fibrosis die of respiratory failure.

In the past, researchers studied Pseudomonas in isolation despite the fact that it's rarely the lone bacterium in the lungs of people with CF. Hoffman decided to study how Pseudomonas and Staphylococcus aureus — the other bacterium most commonly found in the lungs of cystic fibrosis patients — behave when the two are grown togetheIn the past, researchers studied Pseudomonas in isolation despite the fact that it's rarely the lone bacterium in the lungs of people with CF. Hoffman decided to study how Pseudomonas and Staphylococcus aureus — the other bacterium most commonly found in the lungs of cystic fibrosis patients — behave when the two are grown togethein isolation despite the fact that it's rarely the lone bacterium in the lungs of people with CF. Hoffman decided to study how Pseudomonas and Staphylococcus aureus — the other bacterium most commonly found in the lungs of cystic fibrosis patients — behave when the two are grown togethein the lungs of people with CF. Hoffman decided to study how Pseudomonas and Staphylococcus aureus — the other bacterium most commonly found in the lungs of cystic fibrosis patients — behave when the two are grown togethein the lungs of cystic fibrosis patients — behave when the two are grown together.

Pseudomonas aeruginosa can cause serious inflammations of the skin and the lung in patients with a weakened immune system, particularly in those suffering from the genetic disorder cystic fibrosis.

In the Comer Emergency Department, pediatricians, pediatric surgeons, nurses, social workers and other professionals will treat the most complex cases — not only those with traumatic injuries but also patients with all types of severe illnesses who need emergency specialty care, including patients with congenital heart disease, cystic fibrosis, cancer and neurological disorders.

One runner, James Mathis, raised $ 7,295 in donations and in - kind gifts to help cystic fibrosis patients.

Mathis participated in the half marathon with his wife in support of their friend's son who is a patient at Augusta University's Cystic Fibrosis Center.

Hundreds of rare disease biobanks and patient registries already exist in Europe alone, and collaborative initiatives in specific disease groups (e.g. Huntington's disease, cystic fibrosis and neuromuscular diseases) have advanced infrastructure harmonisation in several areas.

We also sequenced several members of the Burkholderia cenocepacia complex that are important pathogens in the lungs of cystic fibrosis patients.

Meanwhile, Hans Clevers and colleagues applied CRISPR to disease correction in adult stem cells isolated from two patients with cystic fibrosis.

Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study».